Gliclazide API (CAS No. 21187-98-4) is a synthetic oral hypoglycemic active pharmaceutical ingredient associated with type 2 diabetes mellitus, sulfonylurea antidiabetic therapy, blood glucose management, and oral antidiabetic pharmaceutical development.
Gliclazide belongs to the sulfonylurea class of oral antidiabetic pharmaceutical compounds.
It is commonly classified as a second-generation sulfonylurea agent.
The primary pharmacological action of Gliclazide involves stimulation of insulin secretion from functioning pancreatic beta cells.
Gliclazide interacts with sulfonylurea receptor-associated ATP-sensitive potassium channels in pancreatic beta-cell membranes.
Inhibition of ATP-sensitive potassium channel activity contributes to membrane depolarization.
Membrane depolarization promotes calcium influx into pancreatic beta cells.
The increase in intracellular calcium stimulates insulin secretion.
Increased insulin release contributes to reduction of elevated blood glucose levels.
Gliclazide is associated with pharmaceutical products developed for the management of type 2 diabetes mellitus.
The compound is used in conventional immediate-release oral tablet formulations and modified-release pharmaceutical formulations.
Modified-release Gliclazide formulations are designed to provide controlled or prolonged release of the active pharmaceutical ingredient.
Pharmaceutical companies sourcing Gliclazide API commonly evaluate chemical identity, HPLC assay, chromatographic purity, related substances, process-related impurities, degradation products, residual solvents, water content, crystal form, polymorphic characteristics, particle size distribution, bulk density, and batch-to-batch consistency.
Because Gliclazide has low aqueous solubility, particle size distribution, crystal characteristics, dissolution-related properties, and formulation compatibility may be important during oral solid dosage-form development.
Particle-size control may influence API dispersion, dissolution characteristics, blend uniformity, content uniformity, and manufacturing consistency.
Impurity-profile control is also important for monitoring synthesis-related impurities, residual starting materials, intermediate-related impurities, and stability-related degradation products.
Swapnroop Drugs and Pharmaceuticals supports Gliclazide API sourcing and supply requirements for qualified pharmaceutical research, antidiabetic drug development, oral tablet formulation, modified-release tablet development, analytical requirements, formulation development, and pharmaceutical manufacturing programs with product-specific documentation and secure pharmaceutical-grade packaging.
Particle size distribution is an important formulation consideration for Gliclazide API because of its low aqueous solubility.
API particle-size characteristics may influence dissolution behavior, powder dispersion, blend uniformity, and oral dosage-form performance.
Crystal form and polymorphic characteristics should be evaluated according to the intended pharmaceutical formulation.
For modified-release dosage-form development, API particle characteristics and drug-polymer compatibility may influence release-profile performance.
* Gliclazide API CAS No. 21187-98-4
* Second-generation sulfonylurea API
* Oral hypoglycemic pharmaceutical ingredient
* Antidiabetic API
* Type 2 diabetes-associated pharmaceutical compound
* Insulin secretagogue
* Pancreatic beta-cell-associated mechanism
* ATP-sensitive potassium channel-associated pharmacology
* Synthetic small-molecule API
* Molecular formula C15H21N3O3S
* Molecular weight 323.41 g/mol
* HPLC purity profile control
* Related substance monitoring
* Process impurity control
* Degradation product monitoring
* Crystal-form characterization
* Polymorphic-form evaluation as applicable
* Particle-size requirement coordination
* Micronized grade requirements coordinated as applicable
* Immediate-release formulation applications
* Modified-release formulation applications
* Residual solvent control according to applicable ICH Q3C requirements
* Elemental impurity evaluation according to applicable ICH Q3D requirements
* Pharmaceutical-grade packaging
* COA and SDS availability as applicable
* Bulk pharmaceutical supply and export coordination